Haleon (NYSE:HLN) Sees Large Volume Increase on Analyst Upgrade

Haleon PLC Sponsored ADR (NYSE:HLN) saw an uptick in trading volume on Friday after Deutsche Bank Aktiengesellschaft upgraded the stock from a sell rating to a hold rating. Approximately 15,343,841 shares traded hands during mid-day trading, an increase of 38% from the average daily volume of 11,082,158 shares. The stock last traded at $8.7460 and had previously closed at $8.57.

HLN has been the topic of several other reports. Morgan Stanley reissued an “overweight” rating on shares of Haleon in a research report on Thursday, August 6th. Wall Street Zen cut shares of Haleon from a “buy” rating to a “hold” rating in a report on Saturday, October 3rd. Zacks Research downgraded shares of Haleon from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 22nd. Royal Bank Of Canada reiterated a “sector perform” rating on shares of Haleon in a research note on Tuesday, August 11th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research report on Friday, September 25th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $4.90.

More Haleon News

Here are the key news stories impacting Haleon this week:

• Positive Sentiment: Haleon announced a £500 million share buyback, which could provide support for the stock by reducing the number of shares outstanding and signaling management’s confidence in the company’s long-term value. Haleon Cuts 2026 Organic Revenue Growth Forecast and Announces Share Buyback
• Positive Sentiment: Deutsche Bank upgraded Haleon from “sell” to “hold,” reducing some of the negative analyst pressure on the shares. However, the change is not a bullish “buy” recommendation and indicates a more cautious rather than optimistic outlook. Deutsche Bank Haleon Rating
• Neutral Sentiment: The third-quarter sales and trading call provided additional detail on the company’s performance and outlook, with investors focused on slowing growth, pricing and consumer demand. Haleon Q3 2026 Sales and Trading Call Transcript
• Negative Sentiment: Haleon cut its 2026 organic revenue growth forecast to 2.5% after a sales miss. The downgrade raises concerns about weaker demand and makes it more difficult for the company to meet growth expectations. Haleon Cuts 2026 Organic Revenue Growth Forecast
• Negative Sentiment: CEO communications reportedly warned employees that “difficult choices” are ahead following the sales shortfall, suggesting potential cost-cutting or restructuring. The coverage reinforces investor concerns about near-term execution and profitability. Haleon CEO Warns of Difficult Choices

Hedge Funds Weigh In On Haleon

Several institutional investors and hedge funds have recently modified their holdings of the company. Root Financial Partners LLC purchased a new position in Haleon during the third quarter worth about $25,000. Western Wealth Management LLC purchased a new stake in shares of Haleon during the first quarter valued at approximately $29,000. Annis Gardner Whiting Capital Advisors LLC grew its stake in Haleon by 402.0% during the 1st quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock valued at $30,000 after purchasing an additional 2,404 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Haleon by 20.4% during the second quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock worth $58,000 after purchasing an additional 1,055 shares during the last quarter. Finally, Fiduciary Financial Group LLC bought a new position in shares of Haleon in the 2nd quarter worth about $97,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Up 1.8%

The firm’s 50 day simple moving average is $9.56 and its 200 day simple moving average is $9.78. The company has a quick ratio of 0.52, a current ratio of 0.69 and a debt-to-equity ratio of 0.38. The company has a market cap of $38.43 billion, a price-to-earnings ratio of 22.40, a price-to-earnings-growth ratio of 2.26 and a beta of 0.14.

About Haleon

Haleon plc (NYSE: HLN) is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company’s products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.